Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors
about
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Inhibition of inflammation and oxidative stress by an imidazopyridine derivative X22 prevents heart injury from obesityTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine DerivativesSmall molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.Covalent-Allosteric Kinase Inhibitors.SPLINTS: small-molecule protein ligand interface stabilizers.Harnessing allostery: a novel approach to drug discovery.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1.Efficient and cost effective production of active-form human PKB using silkworm larvae.SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.Selectivity Mechanism of ATP-Competitive Inhibitors for PKB and PKA.Conformational sampling of membranes by Akt controls its activation and inactivation.
P2860
Q28080599-4EA4655A-7AE3-4D94-8FE5-06A6AD02F0D2Q28384702-9E203BB4-26E8-4575-9E11-562026288265Q28550300-0D421DE8-DC76-46CD-AB59-BDB39D8C7A2FQ33635937-722EDEBD-01C7-4670-98F0-69334D1A9163Q34992505-90E3DBFE-A3F1-4DE9-AD9A-34EC7304076EQ35674207-4FCEABB4-EB7A-45D3-978D-F11EE85994F1Q36805591-A4408F61-DA07-4BBC-9F35-13708FD6D7CDQ38211688-E49CA16E-A491-4A73-AA9E-D5F6F566D2C1Q38989374-175467D4-4C28-4476-BB78-BF385BE19C13Q39226865-8338687B-7716-47E3-BA07-E6DEAA47290EQ41749934-3B707A81-88E8-4355-BA6D-F0894575E412Q42002090-8B7AAACA-79B1-4C81-AE89-EC797F6B2A59Q42317470-E216D6CA-DFF3-42F2-8295-7717A06EED50Q51037064-0E081A53-66F3-4AAB-A6C8-4E30E840C855Q52327556-06D94FB5-0425-43FF-8D0B-C9A17C438C36
P2860
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Discovery and optimization of ...... ATP-independent Akt inhibitors
@ast
Discovery and optimization of ...... ATP-independent Akt inhibitors
@en
Discovery and optimization of ...... ATP-independent Akt inhibitors
@nl
type
label
Discovery and optimization of ...... ATP-independent Akt inhibitors
@ast
Discovery and optimization of ...... ATP-independent Akt inhibitors
@en
Discovery and optimization of ...... ATP-independent Akt inhibitors
@nl
prefLabel
Discovery and optimization of ...... ATP-independent Akt inhibitors
@ast
Discovery and optimization of ...... ATP-independent Akt inhibitors
@en
Discovery and optimization of ...... ATP-independent Akt inhibitors
@nl
P2093
P3181
P356
P1476
Discovery and optimization of ...... ATP-independent Akt inhibitors
@en
P2093
Cathy Bull
Christopher Brassard
Darin Kizer
David Vensel
Dennis S France
Eoin Kelleher
Erika Volckova
Jason Hill
Jean-Marc Lapierre
P304
P3181
P356
10.1021/JM300276X
P407
P577
2012-06-14T00:00:00Z